中华消化杂志
中華消化雜誌
중화소화잡지
Chinese Journal of Digestion
2013年
10期
680-683
,共4页
张馨燕%付娟娟%普文静%孙振柱
張馨燕%付娟娟%普文靜%孫振柱
장형연%부연연%보문정%손진주
胃肿瘤%受体,表皮生长因子%免疫组织化学%原位杂交,荧光%基因扩增
胃腫瘤%受體,錶皮生長因子%免疫組織化學%原位雜交,熒光%基因擴增
위종류%수체,표피생장인자%면역조직화학%원위잡교,형광%기인확증
Stomach neoplasms%Receptor,epidermal growth factor%Immunohistochemistry%In situ hybridization,fluorescence%Gene amplification
目的 检测胃癌组织中人类表皮生长因子受体2(HER2)基因扩增与蛋白表达结果的一致性.方法 收集2010年至2012年120例胃癌患者的胃癌组织标本,其中100份为手术标本,20份为胃镜活组织检查标本.应用免疫组织化学(IHC)方法检测120份标本的HER2蛋白表达情况.根据IHC检测结果,选取IHC切片中HER2阳性部位制作成组织芯片进行荧光原位杂交(FISH),检测HER2的基因扩增情况.对IHC检测灶性(+++)(≤10％的肿瘤细胞强染色)的标本进行不同着色强度部位对比FISH检测.统计学处理采用Kappa检验.结果 120份胃癌组织中,IHC检测显示77份为不同强度阳性染色,其中16份为(+++),6份为灶性(+++),37份为(++),18份为(+),IHC检测HER2蛋白表达阳性率为18.3％(22/120).FISH检测显示41份阳性,HER2基因扩增率为34.2％,其中21份IHC检测为(++),15份为(+++),5份为灶性(+++).IHC与FISH联合检测HER2阳性率为35.0％(42/120).IHC与FISH检测的符合率为91.6％(76/83).Kappa系数为0.960(P＜0.01).对5份FISH阳性且IHC检测为灶性(+++)标本的不同着色强度部位进行对比FISH检测,发现全部扩增.结论 组织芯片技术与IHC技术在胃癌组织中检出HER2具有一致性,并可提高HER2的检出率.
目的 檢測胃癌組織中人類錶皮生長因子受體2(HER2)基因擴增與蛋白錶達結果的一緻性.方法 收集2010年至2012年120例胃癌患者的胃癌組織標本,其中100份為手術標本,20份為胃鏡活組織檢查標本.應用免疫組織化學(IHC)方法檢測120份標本的HER2蛋白錶達情況.根據IHC檢測結果,選取IHC切片中HER2暘性部位製作成組織芯片進行熒光原位雜交(FISH),檢測HER2的基因擴增情況.對IHC檢測竈性(+++)(≤10％的腫瘤細胞彊染色)的標本進行不同著色彊度部位對比FISH檢測.統計學處理採用Kappa檢驗.結果 120份胃癌組織中,IHC檢測顯示77份為不同彊度暘性染色,其中16份為(+++),6份為竈性(+++),37份為(++),18份為(+),IHC檢測HER2蛋白錶達暘性率為18.3％(22/120).FISH檢測顯示41份暘性,HER2基因擴增率為34.2％,其中21份IHC檢測為(++),15份為(+++),5份為竈性(+++).IHC與FISH聯閤檢測HER2暘性率為35.0％(42/120).IHC與FISH檢測的符閤率為91.6％(76/83).Kappa繫數為0.960(P＜0.01).對5份FISH暘性且IHC檢測為竈性(+++)標本的不同著色彊度部位進行對比FISH檢測,髮現全部擴增.結論 組織芯片技術與IHC技術在胃癌組織中檢齣HER2具有一緻性,併可提高HER2的檢齣率.
목적 검측위암조직중인류표피생장인자수체2(HER2)기인확증여단백표체결과적일치성.방법 수집2010년지2012년120례위암환자적위암조직표본,기중100빈위수술표본,20빈위위경활조직검사표본.응용면역조직화학(IHC)방법검측120빈표본적HER2단백표체정황.근거IHC검측결과,선취IHC절편중HER2양성부위제작성조직심편진행형광원위잡교(FISH),검측HER2적기인확증정황.대IHC검측조성(+++)(≤10％적종류세포강염색)적표본진행불동착색강도부위대비FISH검측.통계학처리채용Kappa검험.결과 120빈위암조직중,IHC검측현시77빈위불동강도양성염색,기중16빈위(+++),6빈위조성(+++),37빈위(++),18빈위(+),IHC검측HER2단백표체양성솔위18.3％(22/120).FISH검측현시41빈양성,HER2기인확증솔위34.2％,기중21빈IHC검측위(++),15빈위(+++),5빈위조성(+++).IHC여FISH연합검측HER2양성솔위35.0％(42/120).IHC여FISH검측적부합솔위91.6％(76/83).Kappa계수위0.960(P＜0.01).대5빈FISH양성차IHC검측위조성(+++)표본적불동착색강도부위진행대비FISH검측,발현전부확증.결론 조직심편기술여IHC기술재위암조직중검출HER2구유일치성,병가제고HER2적검출솔.
Objective To investigate the consistency of gene amplification and its expression at protein level of human epidermal growth factor receptor 2 (HER2) in gastric carcinoma.Methods From 2010 to 2012,120 gastric cancer specimens of patients with gastric cancer were collected,of which 100 were surgical specimens and 20 were specimens from biopsy under gastroscope.The protein expression of HER2 in 120 specimens was detected by immunohistochemistry (IHC).According to the results of IHC,the positive parts of HER2 expression of IHC slices were developed into tissue microarrays for fluorescence in situ hybridization (FISH) to test the gene amplification of HER2.The different parts with different color intensity of focal (+ + +) (≤ 10％ tumor cell strongly staining) specimens detected by IHC detection were compared with the results of FISH.Kappa test was performed for statistical analysis.Results Among 120 gastric cancer specimens,the results of IHC indicated that 77 specimens were positive with different staining intensity including 16 strong positive (+++),six focal positive (+++),37 moderate positive (++) and 18 weak positive (+).The positive rate of HER2 protein expression detected by IHC was 18.3％ (22/120).The results of FISH showed 41 specimens were positive and the rate of gene amplification was 34.2％.Among which,21 were moderate positive (++) detected by IHC,15 were strong positive (+ + +) and five were focal positive (+ ++).The positive rate of HER2 was 35.0％ (42/120) with IHC and FISH combined detection.The consistent rate of IHC and FISH was 91.6 ％ (76/83).Kappa coefficient was 0.960 (P＜0.01).In five positive specimens detected by FISH and which were focal positive (+ + +) by IHC,the different parts with different color intensity were compared with the results of FISH and gene amplification was found in all specimens.Conclusion Tissue microarray technology is consistent with IHC in HER2 detection in gastric cancer specimens and could help to improve the detection rate.
